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Abstract
Background:  Leishmaniasis remains a serious public health problem in several parts of the
developing world. Effective prophylactic measurements are hampered by imprecise comprehension
of different aspects of the disease, including its immunoregulation. A better comprehension of
immunoregulation in human VL may be useful both for designing and evaluating
immunoprophylaxis.
Methods: To explore immunoregulatory mechanisms, 20 visceral leishmaniasis (VL) patients were
evaluated during active disease and at different periods up to one year after treatment determining
their plasma cytokine levels, clinical parameters (palpable spleen and liver) and antibody levels.
Results: Elevated plasma levels of IFN-γ and of IL-12 p40 were observed during active disease,
significantly decreasing after treatment whereas in vitro Leishmania antigen-stimulated IFN-γ
production by PBMC exhibited an inverse pattern being low during disease and increasing steadily
thereafter. Absence of IFN-γ activity is a hallmark of VL. The main candidate for blunting IFN-γ
activity is IL-10, a cytokine highly elevated in plasma with sharp decrease after treatment. Activity
of IL-10 is inferred by high levels of anti-Leishmania specific IgG1 and IgG3. TGF-β had elevated
total, but not of active, levels lessening the likelihood of being the IFN-γ counterpart. Spleen or liver
size presented a steady decrease but return to normal values at only 120 days after treatment. Anti-
Leishmania IgG (total and subclasses) levels and DTH or Leishmania-stimulated lymphocyte
proliferation conversion to positive also present a slow decrease after treatment. IL-6 plasma levels
were elevated in only a few patients.
Conclusion: Taken together our results suggest that IFN-γ and IL-10 are the molecules most likely
involved in determining fate of disease. After treatment, there is a long delay before the immune
profile returns to normal what precludes using plasma cytokine levels as criteria of cure as simpler
clinical evaluations, as a palpable spleen or liver, can be used.
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Background
Leishmaniasis remains a serious public health problem in
several parts of the developing world. Effective prophylac-
tic measurements are hampered by imprecise comprehen-
sion of different aspects of the disease, including its
immunoregulation. A better comprehension of immu-
noregulation in human VL may be useful both for design-
ing and evaluating immunoprophylaxis.
Leishmaniases present a wide spectrum of manifestations,
with either tegumentary or visceral involvement. Visceral
leishmaniasis (VL) is a progressive infection with fatal
outcome in the absence of treatment. During disease evo-
lution there is extensive parasite multiplication attaining
a high parasite burden in the spleen and liver. Whereas in
the most common forms of tegumentary leishmaniasis
parasite growth is controlled and an anti-leishmania cell-
mediated immune response (CMI) is mounted [1], lack of
anti-leishmania CMI has been considered a hallmark of
VL [2,3] There has been described a transient incapacity of
mounting an effective CMI in VL based on the absence of
lymphocyte proliferative response as well as IL-2 or IFN-γ
production upon PBMC in vitro stimulation by leishma-
nial antigen [2-4]. VL patients also have negative delayed-
type hypersensitivity skin tests. [5]
The existence of antigen-reactive T cells was suspected
since both in vitro and vivo CMI evaluations turn positive
following cure [2,3,6,7]. Even during active disease, anti-
leishmania IgG3 and IgG4 antibody is detected suggesting
an active T-cell control of antibody production [8]. Addi-
tionally, there is evidence of IFN-γ production during
active human VL as shown by the presence of mRNA in
spleen samples [9] and the presence of high levels of IFN-
γ, and/or of IFN-γ inducing cytokines in plasma [10-13].
Albeit present, IFN-γ is not capable of fully exerting its
activities probably due to the presence of counter regula-
tory products such as IL-10 [14,15].
In the present report, we took advantage of studying a
group of VL patients during active disease and performing
a long follow-up in order to determine their plasma
cytokine levels. Evaluating the presence of cytokines dur-
ing active VL and at various time periods after effective
treatment maps the recovery of the cytokine pattern and
helps understanding immunoregulatory mechanisms in
this complex disease.
Methods
Study design
A prospective study was conducted on 20 patients with
VL, including 12 patients seen at clinics from the Brazilian
public health system and eight patients seen at the Infec-
tious and Parasitic Diseases outpatient clinic at the Federal
University of Maranhão (UFMA), São Luís, MA, Brazil.
Patients (10 males and 10 females) participated in this
study. Clinical and demographic characteristics of the
patients are given in Table I.
The study was performed between August 2000 and July
2002. The study was approved by the Research Ethics
Committee of "Hospital Universitário Presidente Dutra",
and all individuals included in this report, or their legal
guardians, signed an informed consent form before
enrollment. Patients living in the municipalities of São
Luís Island (São Luís, São José de Ribamar, Paço do
Lumiar and Raposa), who had not started VL treatment,
and who agreed to participate in the study were included
in the study. Patients who did not adhere to regular fol-
low-up defined as attendance of the scheduled return vis-
its were excluded. Diagnosis was confirmed by
identification of amastigote forms of Leishmania sp in
Giemsa-stained smears of bone marrow aspirates. All
patients received N-methylglucamine antimonate (Glu-
cantime®) as the drug of first choice at the dose of 20 mg/
Sb5+/kg/day (maximum dose of 810 mg/day), intrave-
nously, over a period of 20 to 30 days. Two adult patients
complained of myalgia at the beginning of treatment but
discontinuation of the drug was not required. No patient
in this series exhibited marked anemia (3+/4+ and/or
hemoglobin ≤ 5 g/dl), hemorrhagic phenomena, severe
diarrhea or severely impaired general and/or nutritional
status. Eight individuals with associated respiratory infec-
tion were treated in hospitals. No differences in clinical or
laboratory parameters were observed between hospital-
ized patients and those treated in outpatient clinics.
Data were collected using a standard protocol chart con-
taining the following information: identification, clinical
complaints, physical exam, and the results of laboratory
tests performed before (day zero) and after therapy (30
days). All patients underwent clinical follow-up every 10
days during treatment, monthly up to 3 months after
treatment, and then every 3 months until completing 12
months. Liver and spleen sizes were evaluated by two
observers by palpation and reported as the distance to the
rib border in cm. Since the significance of the reduction of
a palpable liver or spleen depends on the patient size,
such results are presented both as reduction in cm and as
"percent variation" calculated subtracting the post treat-
ment (30 days) value from the initial value and then
dividing the result by the initial value. Clinical assessment
consisted of recording the symptoms reported by the
patient or responsible person and complete clinical exam-
ination including measurement of spleen and liver size
and weight.
A group of normal volunteers (19) was included in our
study. They were individuals from the same endemic area,BMC Infectious Diseases 2005, 5:113 http://www.biomedcentral.com/1471-2334/5/113
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with the same range age and presenting negative anti-
Leishmania serology and negative anti-parasite DTH.
Samples
Peripheral blood (maximum 20 ml) was collected for
PBMC and plasma. The blood was diluted 1:1 in culture
medium, layered on Ficoll-Hypaque (Sigma-Aldrich, St
Louis, MO) and centrifuged at 400 g for 30 min at room
temperature PBMC recovered from the interface, were
washed twice by centrifuging at 300 g for 10 min.
Antigen
Soluble  Leishmania  antigen (SLA) was prepared as
described elsewhere [2] Briefly, stationary phase promas-
tigotes of Leishmania chagasi were ultrasonicated and cen-
trifuged at 20,000 × g for 2 h. The supernatant was used at
a final concentration of 10 µg/ml.
Cell culture
PBMC were obtained from heparinized venous blood by
passage over a Ficoll Hypaque gradient (Sigma-Aldrich).
PBMC were washed three times and resuspended at a con-
centration of 5 × 106 cells /ml in RPMI 1640 medium
(Gibco, NY) supplemented with 2 mM L- glutamine, pen-
icilin (100 U/ml), streptomicin (100 µg/ml) (Gibco, NY)
and 10% heat inactivated human AB serum (Sigma-
Aldrich). Cells were plated in 24 well tissue culture plates
(Costar, Corning Incorporated, NY) at a concentration of
5 × 106 cells/ml and incubated at 37°C, 5% CO2. Stimu-
lation was performed by addition of SLA (10 µg/ml).
PBMC were stimulated with anti-CD28 plus anti-CD3 (10
µg/ml) as positive controls. Supernatants were harvested
24, 48 and 96 hours after in vitro stimulation and main-
tained at -20°C until use.
Proliferation assays
For lymphoproliferation assays, PBMC (1 × 106 cells/ml)
were plated in 96 well flat bottom plates, 200 µl/well and
stimulated with SLA or anti-CD28 and anti-CD3 as a pos-
itive control, for 5 days at 37°C and 5% CO2. Lymphopro-
liferation was accessed by evaluation of [3H]thymidine
incorporation in beta counter after a 8 hour pulse of cell
cultures with [3H]thymidine (1 µCi/well). Incorporation
of radioactive label was measured by liquid scintillation
(Cell Harvester, FilterMate 196 Perkin Elmer Life Sciences,
MA). Results are expressed as the mean counts per minute
in triplicate cultures (Direct Beta Counter Matrix 9600,
PerkinElmer Life Sciences, MA)
Table 1: Clinical and hematological data on 20 patients with visceral leishmaniasis.
Patient Age Spleen Liver Weight Erythrocytes Hemoglobin
years Size (cm) % var* Size (cm) % var* kg % var* mm3 % var* g/dl % var*
d0 d30 D0 D30 D0 D30 D0 D30 D0 D30
01 5 5 0** -1.00 4 0 -1.00 15 16.5 0.10 2.6 4.3 0.65 7.6 10.5 0.38
02 6 5 4 -0.20 10 8 -0.20 18.5 19.0 0.03 2.7 4.2 0.56 8.0 10.6 0.31
03 1 7 4.5 -0.36 5.5 4 -0.28 7.4 7.9 0.07 1.8 3.5 0.94 3.5 7.9 1.26
04 1 8 4 -0.50 7 4 -0.43 8.0 8.2 0.03 4.1 4.6 0.12 7.6 8.5 0.12
05 3 6.5 3 -0.53 6.5 4 -0.38 11.8 11.9 0.01 2.9 3.0 0.03 5.2 5.4 0.04
06 2.5 7 3 -0.57 7 5 -0.29 11.4 11.5 0.01 3.2 3.8 0.19 8.4 10.9 0.30
07 2 6 3 -0.50 6 4 -0.33 9.6 9.6 0.00 2.5 3.7 0.48 4.0 7.0 0.75
08 9 7 0 -1.00 8.5 6 -0.29 22.5 24.2 0.07 3.0 3.6 0.20 7.8 9.6 0.23
09 5 8.5 3.5 -0.59 7.5 6 -0.20 15.0 15.5 0.03 3.4 3.7 0.09 6.6 7.0 0.06
10 2 8 3 -0.63 8 6 -0.25 11.8 13.0 0.11 3.91 4.8 0.23 8.9 10.6 0.18
11 5 4 3 -0.25 5 3 -0.40 18.0 19.0 0.06 3.0 5.3 0.77 9.3 11.0 0.18
12 6 4 0 -1.00 8 6 -0.25 15.0 15.5 0.03 3.7 4.0 0.08 9.0 10.4 0.16
13 1 6 3 -0.50 7 5 -0.29 6.0 8.3 0.38 2.5 3.4 0.36 7.3 9.8 0.34
14 5 3 0 -1.00 6 3 -0.50 14.9 15.3 0.03 2.5 4.6 0.84 7.3 12.2 0.67
15 16 20 17.5 -0.13 7 5 -0.29 45.0 48.0 0.07 3.0 4.8 0.60 9.0 11.6 0.28
16 23 12 8 -0.33 8 6 -0.25 60.0 65.9 0.10 2.5 3.8 0.52 6.5 8.8 0.35
17 33 6.5 4.5 -0.54 4.5 3 -0.33 39.0 40.0 0.03 3.0 3.3 0.10 8.1 9.2 0.14
18 29 8 4 -0.50 6 4 -0.33 59.0 61.9 0.05 2.8 3.8 0.36 8.4 11.4 0.36
19 51 4.5 0 -1.00 10 3 -0,70 56.6 58.1 0.03 3.9 3.0 -0.23 8.9 8.0 -0.10
20 18 14 5 -0.64 0 0 0.00 52.6 53.3 -0.06 3.4 4.5 0.32 7.3 11.0 0.51
Mean 11.2 7.5 3.8 -0.59 6.6 4.25 -0.35 25.06 26.13 0.06 3.02 3.99 0.36 7.43 9.55 0.33
SD 13.4 3.9 3.9 0.28 2.22 1.97 0.20 19.47 20.09 0.09 0.59 0.63 0.30 1.61 1.80 0.30
* % variation = (d30-d0)/d0.
**0 = not palpable;BMC Infectious Diseases 2005, 5:113 http://www.biomedcentral.com/1471-2334/5/113
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Cytokine ELISA
IL-10, IFN-γ, IL-6 (B&D, San Diego, CA) and TGF-β
(Promega, Madison, WI) levels were determined on cul-
ture supernatants and plasma using commercially availa-
ble ELISA kits. Cultures supernatants were harvested at
different time points: for IFN-γ we harvested the superna-
tant at 72 hours and for IL-10 48 hours after the addition
of stimulus (SLA antigen at 10 µg/ml) We measured active
and total TGF-β, treating the samples by acidification or
not, respectively. The assays were performed according to
the manufacturer's instructions.
Delayed-type hypersensitivity reaction
DTH was performed as previously described [2], using L
chagasi promastigotes (MHOMBR-83-BA-3) antigen. The
test was applied intradermally to the anterior forearm,
and readings were taken 48 to 72 hours after application
(CUBA et al.,1985; WHO,1990), with the diameter of the
induration measured with a millimeter ruler. One or both
diameters equal to or greater than 5 mm were considered
to be a positive reaction. The test was carried out on all
patients before treatment, at the end of treatment and
each month afterwards up to DTH conversion.
ELISA serology
Antileishmanial antibodies were detected by ELISA. Solu-
ble leishmanial antigen (SLA) from L. chagasi was diluted
in buffer (15 mM Na2HCO3, 28 mM NaH CO3, pH 9.6)
to 1 ug/well (50 ul) to coat 96-wells microtiter plates
(Probind; Falcon, Becton Dickinson, Lincoln Park, NJ) by
overnight incubation at 4°C. A solution of PBS plus 1%
Tween 20 was used for one hour at room temperature to
decrease the background. After five washes with PBS plus
0.1% Tween 20 (PBS-T), sera diluted at 1:100 was added
at 50 µl/well and incubated 30 minutes at room tempera-
ture. After another washing cycle, a 1:10,000 dilution of
alkaline phosphatase-conjugated anti-human IgG anti-
body (Sigma Immunochemicals, St. Louis, MO) was incu-
bated at room temperature for 30 minutes. For IgG sub-
classes reactivity, the incubation with human sera (1:100
Clinical and immunological parameters from acute VL at different periods after treatment Figure 1
Clinical and immunological parameters from acute VL at different periods after treatment. Spleen (A) liver (B) 
size and plasma IgG levels and their subclasses (C) from VL patients during acute VL (day 0) and at different periods after treat-
ment (30, 120 and 210 days) are shown. Stimulation index obtained in proliferation assay from PBMC from VL stimulated with 
Leishmania antigen (10 µg/ml) are represented in D.BMC Infectious Diseases 2005, 5:113 http://www.biomedcentral.com/1471-2334/5/113
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dilution) was followed by one hour incubation with a
1:1000 solution of anti-human IgG1, IgG2, IgG3 or IgG4
monoclonal antibodies (Sigma Immunochemical). After
further washing, plates were treated for one hour with a
1:10000 dilution of alkaline phosphatase-conjugated
anti-mouse Ig (Sigma Immunochemical). After further
washings, plates were developed using a chromogenic
solution of p-nitrophenylphosphate in sodium carbonate
buffer pH9.6 with 1 mg/ml of MgCl2. The absorbance was
recorded at 405 nm.
Statistical analysis
Data were analyzed by both between subjects (unpaired
cases) and within subject (paired cases) using Kruskal-
Wallis test followed by Dunn's post test with GraphPad
software version 4.0 (GraphPad Software Inc, San Diego,
CA, USA)
Results
Clinical parameters
Reduction of enlarged spleen or liver with return to nor-
mal impalpable stage has long been used to evaluate cure
in human VL. In the present series reductions of spleen
(Fig. 1A) or liver (Fig. 1B) were observed 30 days after
treatment (p < 0.0001 in both cases), but only few
patients had normal values then. Impalpable organs were
observed in almost all patients only 120 days after treat-
ment.
Antibody levels and cell mediated immune responses
Production of different subclasses of IgG can be used as a
surrogate marker of cellular immune responses developed
by the patients. With this perspective,, we evaluated anti-
leishmania total IgG levels, as well as its subclasses, during
active VL and at different times after treatment. Anti-leish-
IFN-γ and IL-10 levels in plasma and supernatant from PBMC from active VL and at different periods after treatment Figure 2
IFN-γ and IL-10 levels in plasma and supernatant from PBMC from active VL and at different periods after 
treatment. Plasma IFN-γ (A) and IL-10 (C) levels obtained by ELISA from VL patients during acute VL (day 0) and at different 
periods after treatment (30, 120 and 210 days) are shown. IFN-γ (B) and IL-10 (D) production obtained from PBMC from VL 
patients during acute VL (day 0) and at different periods after treatment (30, 120 and 210 days) restimulated in vitro for 72 
hours with SLA (10 µg/ml) are shown.BMC Infectious Diseases 2005, 5:113 http://www.biomedcentral.com/1471-2334/5/113
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mania antibodies are present in all subclasses except for
IgG2, with a predominance of IgG1 and a modest increase
of IgG4 (Fig. 1C). All elevated IgG levels drop gradually,
but only IgG4 returned to below cut-off levels 30 days
after treatment. Evaluation of anti-leishmania IgE did not
exhibit a decreasing pattern after treatment (data not
shown).
Conversion of DTH to positive demonstrates the recovery
of CMI in VL patients. However, our results show that
conversion of DTH was positive in less than 50% of tested
individuals 210 days after treatment, reaching 100% con-
version only after 390 days of cure (data not shown).
Despite being submitted to repeated DTH reactions the
patients in the present series exhibited a slow rate of DTH
conversion, a finding against a possible sensitization by
the antigen. Leishmania antigen-stimulated PBMC prolif-
eration has also been largely used for gauging the appear-
ance of anti-parasite specific cell-mediated immunity in
VL patients. Only two patients of the present series had
stimulation indexes above two during active disease (Fig.
1D), with these numbers increasing to only seven by 30
days after treatment and to 15 positive tests at 120 days
post-treatment (Fig. 1D). Increase of stimulation index
was significant (p = 0.0014) but differences between each
time point and day 0 were significant only at day 210
post-treatment. We used anti-CD3 and anti-CD28 as pos-
itive controls in these proliferation assays and we verified
that the stimulation indexes ranged from 20 to 30.
Cytokine levels
Plasma IFN-γ levels are elevated during active disease
(time 0) reaching 470.2 ± 143.4 pg/ml (n = 20) whereas
normal individuals from the same endemic area exhibited
levels of 15.4 ± 3.8 (n = 19). There was a significant
decrease (p = 0.0012) in plasma IFN-γ levels in VL patients
30 days after treatment (155.0 ± 61.1 pg/ml), returning to
the normal range 120 days post-treatment (13.7 ± 9.9; Fig.
2A). Conversely, leishmania-antigen-stimulated PBMC
from VL patients do not produce IFN-γ during active dis-
ease and exhibit a significant progressive increase thereaf-
ter (p = 0.006; Fig. 2B).
Plasma levels of IL-10 were elevated during active disease
(498.4 ± 97.2 pg/ml; n = 20) whereas plasma levels of IL-
10 were undetectable in normal individuals from the
same endemic area (n = 19). Similar to the pattern
observed with IFN-γ, IL-10 circulating levels dropped dra-
matically 30 days after treatment (127.2 ± 125.9 pg/ml,
statistically different from day zero with p < 0.001; Fig.
2C). In vitro PBMC-produced IL-10 remained low during
the whole period (Fig. 2D) did not increasing in any
period post-treatment.
Drop of plasma levels from 0 to 30 days of treatment was
more consistent with IL-10 than IFN-γ (Fig. 2A and 2C).
When evaluating antigen-driven PBMC cytokine produc-
tion a different picture emerged as change in IFN-γ levels
had a consistent rising time dependent pattern and IL-10
Plasma cytokine levels from active VL and at different periods  after treatment Figure 3
Plasma cytokine levels from active VL and at differ-
ent periods after treatment. Plasma IL-12 p40 (A), total 
(open symbols) and active (closed symbols) TGF-β (B) and 
IL-6 (C) levels obtained by ELISA from VL patients during 
acute VL (day 0) and at different periods after treatment (30, 
120 and 210 days) are shown in A, B, C, respectively.BMC Infectious Diseases 2005, 5:113 http://www.biomedcentral.com/1471-2334/5/113
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levels had a fluctuating pattern alternating rises and falls
in different patients (Fig. 2B and 2D).
IL-12 p40 plasma levels were highly elevated in five
patients and moderately elevated in all other patients dur-
ing active VL, with a steady declining pattern in function
of time (p = 0.0007) being very low or negative in all of
them by 210 days after treatment (Fig. 3A). Total, but not
active, plasma TGF-β was elevated pre-treatment and
remained at the same levels at all periods evaluated, and
differences were not significant (Fig. 3B), proving un
unreliable marker of cure. Plasma levels IL-6 were elevated
during active disease in only a subgroup of patients drop-
ping consistently over time post-treatment (p = 0.03; Fig.
3C). Interestingly, patients presenting higher levels of
cytokines (IFN-γ, IL-10, Il-12 or IL-6) were not the same
who showed larger spleen or liver size.
Discussion
In the present report we studied 20 VL patients during
active VL and at different time periods after treatment
evaluating their cytokine and IgG levels in order to
explore the time-dependent alterations of their cytokine
patterns both for contributing for the comprehension of
immunopathogenesis and for better defining criteria for
cure. There is a marked diversity between high plasma lev-
els of IFN-γ and the absence of its production by stimulat-
ing PBMC with leishmanial antigen during active VL.
Following treatment, there is a drop in IFN-γ serum levels
with concomitant rise in its production by PBMC. This
might indicate that antigen-specific IFN-γ-producing cells
are not circulating during active disease being released
when the parasite load declines.
Our data confirm previous observations that during active
human VL there is an abundant production of several
cytokines [10-12,16-18]. In the present report we confirm
that circulating levels of IL-12 p40 and IFN-γ itself are ele-
vated during active VL. IFN-γ has a largely accepted role in
stimulating macrophage leishmanicidal activity [19-21]
and its high serum levels during active VL does not recon-
cile with large parasite burdens observed in this disease.
IFN-γ in sera from active VL patients did not show anti-
viral activity which was present in sera from tegumentary
leishmaniasis or recovered VL individuals [22]. Lack of
IFN-γ activity may be related to the simultaneous presence
of elevated levels of IL-10, as IL-10 seems to be the main
macrophage deactivating cytokine in human leishmania-
sis [12,14]. We cannot rule out the role of other cytokines
able to counteract IFN-γ activities such as TGF-β [23-25].
The observed fall in IL-10 levels following treatment is
coincident to the control of parasite growth lending sup-
port to an important role of this cytokine in human VL.
The relative abundance of different subclasses of patho-
gen-specific antibody provides a good indication of the
Th1/Th2 nature of systemic response in mice [26]. Deter-
mining Th1/Th2 predominance in human immune
responses during leishmaniasis is not as clear [3,18,27].
The present report shows a high level of anti-Leishmania
IgG, mainly comprised of IgG1 and IgG3 subclasses, with
irrelevant or no increase in IgG4 or IgG2 levels in VL
patients. Similar observations have been made in several
parts of the World [28-32] whereas some cases from India
present increased specific IgG2 levels [32,33]. We have,
similarly to others, observed a modest elevation of Leish-
mania-specific IgG4, a subclass that has been linked to a
Th2 (IL-4 or IL-13) response. However it has been difficult
to detect IL-4 in sera from VL patients [10-12,34]. On the
other hand, high levels of anti-Leishmania IgG1 and IgG3
subclasses and very low or absent IgG2 levels have been
reported in VL [28,29,31-33] as observed in the present
series. IgG2 production in man seems to depend on the
IFN-γ/IL-12 influence (reviewed in [35]. IgG1 and IgG3
production although occasionally related to a Th1 human
response [36], has been consistently linked in human par-
asitic infections to IL-10 [35]. The observed pattern of par-
asite-specific subclasses reinforces the notion of a major
role of IL-10, leading to high IgG1 and IgG3 production,
even blunting IFN-γ activity (irrelevant IgG2 production).
Elevated levels of TNF-α have been described in active VL
with a marked fall after treatment [12,18,37], leading to a
suggestion of its use as a criterion of cure. Patients in the
present series exhibited very low plasma TNF-α levels.
Early diagnosis, as in the present series, may find patients
with low TNF-α levels. On the other hand, TNF-α is a very
labile molecule and since we could not exclude problems
in TNF-α measurement, these data are not reported. Most
of the patients studied in this report were seen in outpa-
tients' clinics, and their recovery occurred in a short period
of time, probably reflecting early diagnoses. Previous
reports dealt mainly with advanced in hospital VL cases
and these factors might explain the differences in TNF-α
levels.
A special mention should be given to DTH conversion. In
the present series, no DTH conversion was observed
before 120 days of treatment and even after 210 days only
40% of patients had a positive DTH. Only after a full year
after effective treatment 100% of studied patients exhib-
ited a positive DTH. Other series have reported faster DTH
conversion rates [3]. It is possible that the early diagnosis
and treatment as performed in our patients precluded a
large expansion of antigen-reactive cells making their
post-cure expansion more fastidious, whereas patients
that experience a longer disease period have further
expansion of their reactive cells.BMC Infectious Diseases 2005, 5:113 http://www.biomedcentral.com/1471-2334/5/113
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Plasma levels of IL-10 show a marked decrease in most
patients already 30 days after end of treatment. IL-10 lev-
els remain detectable even after 210 days but all levels
substantially lower than observed during active disease.
Lymphocyte proliferation or PBMC IL-10 production in
response antigen-stimulation do not exhibit a similar
clear pattern as responses fluctuate among patients.
The high levels of IFN-γ observed during active VL are
sharply decreased in most patients by 30 days post treat-
ment and are almost vanished 120 days after treatment. In
vitro antigen-stimulated IFN-γ production shows a specu-
lar image, being negative in all patients during active dis-
ease, positive in approximately 50% of patients by 30 days
post-treatment and detectable in almost all of them by
120 days. Determining in vitro cytokine production is
more cumbersome and expensive than evaluating it in
plasma or serum.
Conclusion
Plasma cytokine levels show high levels of products with
largely opposed functions being difficult to determine
which predominates. IFN-γ and IL-10 are the molecules
most likely involved in determining fate of disease, and
after treatment, there is a long delay before the immune
profile returns to normal. Despite this delay, such return
occurs earlier than other parameters previously proposed
such as IgG levels, TNF-α circulating levels or DTH conver-
sion. However, measuring circulating IFN-γ and/or IL-10
are not useful surrogate markers of cure in human VL as
simpler clinical evaluations (absence of a palpable spleen
or liver e.g.) can be used.
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